Department of Pediatrics, Pediatric Intensive Care Unit, Federal University of São Paulo, São Paulo, Brazil.
J Pediatr Gastroenterol Nutr. 2012 May;54(5):620-3. doi: 10.1097/MPG.0b013e31824a0149.
There is no evidence-based consensus on the use of peptide-based formulas for critically ill children. The present study aimed to identify the factors associated with the choice of peptide-based formulas in the first enteral nutrition prescription for critically ill children and to compare the direct costs of the enteral formulas used in a pediatric intensive care unit.
In a prospective study, children admitted to the intensive care unit and receiving tube feeding for ≥48 hours were evaluated. The potential exposure variables for the use of peptide-based formulas as the first nutrition prescription were age, sex, malnutrition, sepsis/septic shock, fasting period >2 days, use of α-adrenergic drugs before initiating first diet, and the revised Pediatric Index of Mortality score. A direct cost comparison of prescribed formulas was performed.
Of 291 patients included, 85 (29.2%) were given peptide-based formulas in the first nutrition prescription. This choice was independently associated with malnutrition (odds ratio [OR] 2.94; 95% confidence interval [CI] 1.60%-5.39%; P < 0.01), fasting period >2 days (OR 3.46; 95% CI 1.93%-6.20%; P < 0.01), and use of α-adrenergic drugs (OR 2.32; 95% CI 1.24%-4.31%; P < 0.01). Peptide-based formula costs were up to 10 times higher than standard polymeric formula costs.
The choice of peptide-based formula as the first enteral nutrition prescription is associated with the greater severity of patients' clinical status-patients receiving α-adrenergic drugs, those who are malnourished, and those with longer fasting periods. These prescriptions engender costs higher than those associated with standard polymeric formula.
目前尚无循证医学共识支持在危重症患儿中应用肽类配方。本研究旨在确定选择肽类配方作为危重症患儿首次肠内营养配方的相关因素,并比较儿科重症监护病房(PICU)中使用的肠内配方的直接成本。
本前瞻性研究纳入了入住重症监护病房并接受管饲喂养≥48 小时的患儿。可能导致选择肽类配方作为首份营养处方的暴露变量包括年龄、性别、营养不良、脓毒症/脓毒性休克、禁食时间>2 天、开始首份饮食前使用α-肾上腺素能药物,以及改良儿科死亡风险评分。对处方配方进行了直接成本比较。
291 例患儿中,85 例(29.2%)在首份营养处方中使用了肽类配方。这种选择与营养不良(比值比[OR] 2.94;95%置信区间[CI] 1.60%-5.39%;P<0.01)、禁食时间>2 天(OR 3.46;95% CI 1.93%-6.20%;P<0.01)和使用α-肾上腺素能药物(OR 2.32;95% CI 1.24%-4.31%;P<0.01)独立相关。肽类配方的费用高达标准聚肽配方的 10 倍。
选择肽类配方作为首份肠内营养配方与患者临床状态严重程度相关,包括使用α-肾上腺素能药物、营养不良和禁食时间较长的患者。这些处方的费用高于标准聚肽配方。